Breast cancer

What are the 2 important neoadjuvant trials for pertuzumab?

NEOSPHERE – trastuzumab versus trastuzumab plus per to Zometa versus trastuzumab plus rituximab
plus paclitaxel in the neoadjuvant setting resulted in a patient complete pathologic response of 46%
TRYPHAENA – FEC + TP + taxane vs TCHP in the neoadjuvant setting

en_USEnglish